Shares of Achieve Life Sciences Inc. (ACHV) are up over 30% in pre-market trading on Friday, following encouraging final data from its phase I/II multi-dose, pharmacokinetic and pharmacodynamics clinical study of Cytisinicline in smokers.
Asian stocks ended mixed on Friday as hopes for Chinese stimulus helped offset weak economic readings from the U.S. and Europe.
Investors continued to keep a close eye on high-level talks between U.S. and Chinese trade negotiators in Washington, as the two sides face a March 1 deadline to avoid a...
Today's Daily Dose brings you news about Exact Sciences' better-than-expected Q4 financial results; Merck's acquisition of Immune Design; Nevro's lackluster revenue outlook; Opiant Pharma' s disappointing Bulimia Nervosa study results; and near-term catalyst of Zosano Pharma.
The FDA has added Boxed Warning to the label of gout medicine Uloric that highlights the increased risk of death with the drug.
The World Health Organization has warned consumers to be on vigil against fake versions of leukemia drug Iclusig sold in Europe and the Americas.
Today's Daily Dose brings you news about Achieve Life Sciences' progress in ORCA-1 trial; Agios Pharma's near-term regulatory catalyst; new development related to ARCA biopharma's PRECISION-AF pivotal study; financial outlook of Genomic Health and NuVasive; near-term clinical trial catalyst of Sarepta; and partial clinical hold on Xencor's phase I acute myeloid leukemia trial.
The following are some of today's top gainers in the pharma/biotech sector.
Eton Pharmaceuticals Inc. (ETON), which made its public debut last November, touched a new high of $7.49 yesterday.
Today's Daily Dose brings you news about Bausch Health's acquisition of the U.S. rights to Eton Pharma's EM-100 eye drop; Cellular Biomedicine's business highlights and financial results for Q4, 2018; CE Mark approval for Edwards Lifesciences' PASCAL transcatheter valve repair system; Invitae's better-than-expected Q4 financial results among others.
The following are some of today's top gainers in the pharma/biotech sector.